ACTUATE THERAPEUTICS

ACTUATE THERAPEUTICS

Actuate Therapeutics was established in 2017 in Chicago, Illinois, by a trio of medical and scientific heavyweights: Dr. Daniel Von Hoff, a long-time principal investigator of early-phase oncology trials; Dr. Linda Malkas, the biologist who characterized the target; and Dr. Robert Stocum, who came from the oncology and pharmacology side. The founding was not a platform roll-up — it was a single-molecule bet on GSK-3β inhibition, an area that most large pharma companies had probed but abandoned for fear of off-target toxicity. Von Hoff’s involvement brought immediate credibility, linking the startup to the clinical network at the Translational Genomics Research Institute. Actuate pursues a single-asset strategy centered on elraglusib (9-ING-41), a small-molecule GSK-3β inhibitor. The mechanism aims to disrupt both the tumor’s own survival pathways and its capacity to resist platinum-based chemotherapies. This shifts the clinical focus from front-line monotherapy to second- and third-line combination regimens — enrolling patients with pancreatic cancer, glioblastoma, and pediatric sarcomas in investigator-sponsored and company-run Phase 2 trials. Preclinical data suggest that elraglusib degrades beta-catenin and downregulates checkpoint proteins, creating a window where tumors become transiently vulnerable to gemcitabine or cisplatin. The company has forged academic partnerships across the United States, with active clinical sites at centers like the Dana-Farber Cancer Institute and the University of Texas MD Anderson Cancer Center. The firm is small and clinical-stage — its public disclosures show a lean, out-sourced operating model reliant on contract research organizations. Actuate’s financing came through a Series B in 2021 and subsequent bridge rounds, with named investors including Kairos Ventures, DEFTA Partners, and Hatteras Venture Partners. It does not disclose total deployment or team headcount. In May 2023, the company presented updated median overall survival data from its pancreatic cancer cohort at the American Society of Clinical Oncology annual meeting, reporting a signal of extended survival in a subgroup receiving elraglusib plus gemcitabine/nab-paclitaxel compared to historical controls (per the firm’s ASCO abstract, June 2023). What differentiates Actuate structurally is its tight coupling to a single academic investigator’s life work — Malkas spent decades on the target before the company existed, and Von Hoff has designed protocols around its clinical behavior rather than fitting the molecule into standard off-the-shelf trial templates. The company is not a portfolio of assets; it is a single thesis executed through a grant-like network of investigator-initiated trials. This lowers burn but concentrates binary risk entirely on one mechanism and one lead investigator’s clinical reputation.